1 ed male rats that received the D1 antagonist Schering 39166 prior to their first sexual experience ha

2                                 Cyproterone (Schering AG) is clinically used as an antiandrogen for i

3 nhanced (120 mL of iopromide, Ultravist 300; Schering, Berlin, Germany) thoracic abdominopelvic CT.

4 We describe the use of two CCR5 antagonists, Schering-C (SCH-C), which is specific for CCR5, and TAK-

5 cal Research Council (London, UK), Novartis, Schering Health Care, Chugai, Pharmion, Celgene, and Ort

6 restricted educational grants from Novartis, Schering Health Care, Chugai, Pharmion, Celgene, and Ort

7 acrophage colony-stimulating factor (GM-CSF; Schering, Kenilworth, NJ).

8 ational Cancer Institute, Bayer Oy (formerly Schering Oy).

9 rn Ireland, Biogen Idec, Merck Serono, Bayer Schering Pharmaceuticals, Teva Pharmaceuticals Industrie

10  approval and commercialization, Codexis and Schering-Plough (now Merck) jointly developed a chemoenz

11 to screen a database of about a half million Schering-Plough compounds.

12                       Temozolomide (Temodar; Schering-Plough Corp, Kenilworth, NJ) is an imidazole te

13                                        Merck/Schering-Plough Pharmaceuticals; Australian National Hea

14 antagonists as anti-HIV-1 agents reported by Schering-Plough Research Institute in recent years.

15        We evaluated the response to Temodal (Schering-Plough Research Institute, Kenilworth, NJ) of p

16 Dutch College of Health Insurance Companies, Schering-Plough, and Janssen.

17 randomized controlled study of IFN alpha-2b (Schering-Plough, Kenilworth, NJ) administered at maximum

18 itish Heart Foundation, Pfizer, AstraZeneca, Schering-Plough, National Institute for Health Research,